Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis (Q46095258)

19 December 2017

meta-analysis

0 references

title

Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis (English)

1 reference

19 December 2017

author

Eric J. Topol

8

1 reference

19 December 2017

Derek P Chew

4

object named as

Derek Chew

1 reference

19 December 2017

2

A Michael Lincoff

1 reference

19 December 2017

5

Kathy Wolski

1 reference

19 December 2017

John A Bittl

3

object named as

John A Bittl

1 reference

19 December 2017

Ramin Ebrahimi

1

object named as

Ramin Ebrahimi

1 reference

19 December 2017

author name string

Nitin Wadhan

6

1 reference

19 December 2017

Edward J Toggart

7

1 reference

19 December 2017

publication date

1 December 2005

1 reference

19 December 2017

Journal of Cardiovascular Pharmacology and Therapeutics

published in

1 reference

19 December 2017

volume

10

1 reference

19 December 2017

issue

4

1 reference

19 December 2017

page(s)

209-216

1 reference

19 December 2017

Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice G

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Heparin dosing in patients undergoing coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Diabetes mellitus is associated with a shift in the temporal risk profile of inhospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840501000401

10.1177/107424840501000401

21 January 2018

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017